XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Deficit) (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Feb. 20, 2018
Jan. 02, 2017
Feb. 12, 2016
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Jan. 24, 2018
Dec. 31, 2016
Stock options outstanding       3,846,299   3,566,299   2,484,445
Stock options outstanding weighted average exercise price       $ 1.36   $ 1.33   $ 1.18
Stock options intrinsic value       $ 181,537        
Number of stock options granted       280,000   1,103,000    
Stock option weighted average exercise price per share       $ 1.75   $ 1.68    
Stock options granted, term       8 years 18 days   9 years 9 months 25 days    
Number of stock options vested       (296,609)        
Class of warrant or right, outstanding       3,826,658   3,826,658    
Class of warrant or right, outstanding, weighted average exercise price       $ 1.05   $ 1.05    
Series B Preferred Stock [Member] | Private Placement [Member]                
Class of warrant or right, number of securities called by warrants or rights       423,291        
Class of warrant or right, exercise price of warrants or rights     $ 1.25 $ 1.25        
Class of warrant or right, expiration period     5 years 5 years        
Protagenic Therapeutics Inc [Member]                
Debt instrument, face amount       $ 665,000        
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                
Class of warrant or right, number of securities called by warrants or rights       295,945        
Class of warrant or right, exercise price of warrants or rights       $ 1.25        
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                
Class of warrant or right, number of securities called by warrants or rights       127,346        
Class of warrant or right, exercise price of warrants or rights       $ 1.25        
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Private Placement [Member]                
Class of warrant or right, number of securities called by warrants or rights       3,403,367        
Class of warrant or right, exercise price of warrants or rights       $ 1.05        
Four Consultant [Member]                
Number of stock options granted       80,000        
Stock option granted vesting period       48 months        
Stock options granted, term       10 years        
Number of stock options vested       50,000        
Former Consultant [Member]                
Stock options outstanding weighted average exercise price       $ 1.75        
Consulting Agreement [Member] | Neuro Assets Sarl [Member]                
Share-based compensation arrangement by share-based payment award, number of shares authorized             200,000  
Employee [Member]                
Compensation expense       $ 166,213        
Non-Employee [Member]                
Compensation expense         $ 178,434      
Four Consultants [Member] | Over Fourty Eight Months [Member]                
Number of stock options vested       30,000        
Stock Option [Member]                
Number of stock options granted       280,000 150,000      
Stock option weighted average exercise price per share       $ 1.75 $ 1.25      
Compensation expense       $ 344,647 $ 355,336      
Employee Stock Option [Member]                
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 1,825,468        
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition       2 years 11 months 4 days        
Employee Stock Option [Member] | Employee [Member]                
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 897,671        
Employee Stock Option [Member] | Non-Employee [Member]                
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 927,797        
The 2016 Plan [Member]                
Number of additional shares grants for issuance   564,378            
Number of shares available for grant   2,712,678            
Share-based payment award, expiration period   10 years            
2016 Equity Compensation Plan [Member]                
Stock options outstanding weighted average exercise price $ 1.75              
Stock option granted vesting period 48 months              
Stock options granted, term 10 years              
2016 Equity Compensation Plan [Member] | Consulting Agreement [Member]                
Share-based compensation arrangement by share-based payment award, number of shares authorized 200,000              
Stock option granted vesting period 48 months              
Stock options granted, term 10 years